Motzer RJ, Penkov K, Haanen JBAG, et al. JAVELIN Renal 101: A randomized, phase III study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC). ESMO 2018, abstract LBA6_PR.
Pembrolizumab bij patiënten met NSCLC en performance status 2
mei 2020 | Immuuntherapie, Longoncologie